In a rapidly changing industry environment,
we are committed to restoring trust and realizing our “Long-Term Vision 2035.”
We would like to express our sincere gratitude for your continued support.
I was appointed President and CEO of Nihon Chouzai Co., Ltd. on June 25. As the new president, I am fully committed to strengthening our management foundation and enhanceing corporate value to meet shareholder expectations.
Choseido Pharmaceutical Co., Ltd., a member of our group, received administrative disposition on March 27, 2025, due to manufacturing management deficiencies at Kawauchi Plant. We sincerely apologize for the significant concern and inconvenience caused to our patients, their families, medical professionals, and all other stakeholders. We take this administrative disposition seriously and are working collaboratively as a group to ensure the steady implementation of Choseido Pharmaceutical's business improvement plan, as well as to prevent recurrence and improve quality control.
In the Dispensing Pharmacy Business, the number of prescriptions increased year on year due to the effects of new store openings and growth exceeding the previous year in acute diseases, and sales expanded steadily. In the Pharmaceutical Manufacturing and Sales Business, despite contributions from existing products and newly listed drugs, sales and profits declined due to the continuing impact of manufacturing management deficiencies. In the Medical Professional Staffing and Placement Business, the performance of the mainstay pharmacist staffing and placement business continued to expand.
The environment surrounding dispensing pharmacies, our core business, is undergoing significant changes, with increasing demands for enhanced family pharmacy functions, at-home medical care, and medical DX. The Group will fortify its capabilities in online medical care, at-home medical care, and specialty drugs. In the Pharmaceutical Manufacturing and Sales Business, we will not only develop new products but also promote further efficiency improvements in production. In the Medical Professional Staffing and Placement Business, we will focus on developing new businesses that will become new sources of revenue by strengthening our pharmacist business and evolving our business portfolio. We will promote these initiatives based on our Long-Term Vision 2035 announced in September 2024, with the aim of achieving further growth and improved profitability.
We are united as a group in addressing current management challenges and pursuing long-term growth. We sincerely ask for your continued understanding and support.
Kazunori Ogi
President and CEO
